Profile data is unavailable for this security.
About the company
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.
- Revenue in USD (TTM)34.12bn
- Net income in USD5.24bn
- Incorporated1901
- Employees43.00k
- LocationEli Lilly and CoLilly Corporate CtrDrop Code 1094, Lilly Corporate CtrINDIANAPOLIS 46285-0001United StatesUSA
- Phone+1 (317) 276-2000
- Fax+1 (317) 276-3492
- Websitehttps://www.lilly.com/
Mergers & acquisitions
| Acquired company | LLY:NYQ since announced | Transaction value |
|---|---|---|
| Mablink Bioscience SAS | 17.79% | -- |
| POINT Biopharma Global Inc | 34.93% | 1.38bn |
| Versanis Bio Inc | 67.08% | 1.93bn |
| Emergence Therapeutics AG | 58.34% | 8.33m |
| Sigilon Therapeutics Inc | 58.34% | 316.64m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | 58.50bn | 2.13bn | 143.77bn | 88.00k | 70.68 | 1.61 | 16.99 | 2.46 | 0.3593 | 0.3566 | 10.29 | 15.77 | 0.2761 | 1.88 | 5.29 | 664,738.60 | 1.03 | 8.20 | 1.30 | 10.40 | 69.24 | 69.34 | 3.71 | 22.68 | 0.6935 | -- | 0.446 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| AbbVie Inc | 54.32bn | 4.82bn | 291.55bn | 50.00k | 60.55 | 28.07 | 21.44 | 5.37 | 2.72 | 2.72 | 30.63 | 5.87 | 0.3972 | 4.75 | 4.85 | 1,086,360.00 | 3.56 | 6.55 | 4.73 | 8.40 | 66.45 | 69.74 | 8.97 | 16.46 | 0.7638 | 9.12 | 0.851 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
| Merck & Co Inc | 60.11bn | 365.00m | 317.21bn | 72.00k | 960.28 | 8.44 | 74.66 | 5.28 | 0.1304 | 0.1304 | 23.74 | 14.84 | 0.557 | 2.59 | 6.07 | 834,916.70 | 0.3493 | 7.70 | 0.4548 | 10.29 | 73.53 | 72.26 | 0.6271 | 15.03 | 1.00 | 7.61 | 0.4823 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
| Johnson & Johnson | 81.80bn | 18.75bn | 351.20bn | 131.90k | 19.39 | -- | 18.86 | 4.29 | 7.51 | 16.07 | 32.76 | -- | -- | -- | -- | 620,136.40 | -- | 8.93 | -- | 11.96 | 70.22 | 68.17 | 22.92 | 18.86 | -- | -- | -- | 71.25 | 6.46 | 0.8622 | -18.59 | -2.72 | 4.36 | 5.83 |
| Eli Lilly And Co | 34.12bn | 5.24bn | 709.22bn | 43.00k | 128.59 | 65.74 | 104.80 | 20.78 | 5.80 | 5.80 | 37.81 | 11.35 | 0.6013 | 1.40 | 4.27 | 793,583.80 | 9.23 | 11.71 | 15.22 | 17.33 | 79.25 | 77.34 | 15.36 | 20.24 | 0.7311 | 31.05 | 0.699 | 58.45 | 19.56 | 9.69 | -16.08 | 9.52 | 19.62 | 14.97 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 68.11m | 7.16% |
| PNC Bank, NA (Investment Management)as of 31 Dec 2023 | 51.69m | 5.44% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 40.84m | 4.30% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 33.79m | 3.55% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 29.38m | 3.09% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 26.95m | 2.84% |
| PRIMECAP Management Co.as of 31 Dec 2023 | 22.20m | 2.34% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 20.74m | 2.18% |
| State Farm Investment Management Corp.as of 31 Dec 2023 | 16.36m | 1.72% |
| Geode Capital Management LLCas of 31 Dec 2023 | 15.96m | 1.68% |
